Switching from Ozempic to Zepbound
The short answer
For switching from Ozempic to Zepbound, the Zepbound label gives no steps for people coming from Ozempic or any other GLP-1 medicine. It states one starting dose for all uses, 2.5 mg once weekly for 4 weeks, then 5 mg. Self-pay Zepbound vials cost $299 a month at that starting dose through LillyDirect. Your prescriber decides your dose and timing.
Key takeaways
- No label gives a Zepbound dose that matches your Ozempic dose. Your prescriber decides where you start.
- Zepbound's label says using it with any GLP-1 medicine, Ozempic included, isn't recommended. Ozempic ends before Zepbound begins.
- At regular cash prices, Zepbound 2.5 mg costs less than Ozempic 0.5 mg or 1 mg. Higher Zepbound doses cost more than Ozempic 1 mg, and less than Ozempic 2 mg if you refill on time.
- Ozempic is approved for type 2 diabetes. Zepbound is approved for weight and sleep apnea, so plans apply different rules.
- On Medicare with type 2 diabetes? You aren't eligible for the GLP-1 Bridge.
What the labels say about switching from Ozempic to Zepbound
The Zepbound label gives one starting dose for everyone: 2.5 mg once weekly. It gives no dose conversion from Ozempic.
The recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks. The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.
The Zepbound label gives no instructions for switching from another GLP-1 medicine; it only gives the starting dose (2.5 mg once weekly).
FDA label: Revised: 8/2026 (DailyMed version 40)
The Zepbound label says using Zepbound together with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.
ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.
FDA label: Revised: 8/2026 (DailyMed version 40)
| How you pay | Per fill | |
|---|---|---|
| Ozempic 2 mg | NovoCare self-pay | $499 |
| Zepbound 2.5 mg | Measured | $348 |
Try other combinations in the switching planner. Switching is a prescriber decision.
Going from Ozempic to Zepbound changes more than the brand name. Ozempic is semaglutide from Novo Nordisk, approved for adults with type 2 diabetes. Zepbound is tirzepatide from Eli Lilly. It’s approved to reduce excess body weight and keep it off in adults with obesity, or with overweight and a weight-related condition. It’s also approved for moderate to severe obstructive sleep apnea in adults with obesity. So you’re changing the molecule, the company and the approved use.
What do the labels say?
The Zepbound label gives no steps for switching from another GLP-1 medicine. It gives a starting dose and says nothing about what you took before. The Ozempic injection label has nothing on leaving Ozempic for a different medicine.
The one label statement that applies is a limitation of use. Zepbound contains tirzepatide, and using it with other tirzepatide-containing products, or with any GLP-1 receptor agonist, isn’t recommended. Ozempic falls in that second group.
What dose does the Zepbound label start at?
For all uses, the recommended starting dose is 2.5 mg injected once weekly for 4 weeks. The label then raises it to 5 mg, and allows more increases in 2.5 mg steps after at least 4 weeks on the current dose. The 2.5 mg dose is only for getting started. It isn’t approved as a maintenance dose (a dose you stay on). For weight reduction, the maintenance doses are 5 mg, 10 mg or 15 mg once weekly, and 15 mg is the top dose.
The label doesn’t describe a different starting point for someone who has been on Ozempic 1 mg or 2 mg. We don’t translate one drug’s dose into the other’s.
What does it cost before and after?
Zepbound’s self-pay price depends on the form. Single-dose vials from LillyDirect cost $299 a month at 2.5 mg, $399 at 5 mg, and $449 at 7.5 mg and above. The higher strengths keep that price only if you refill within 45 days. A late refill of 10 mg costs $699. The 45-day rule page explains the window.
Compare that with what you pay now. Through NovoCare, Ozempic is $349 a month at 0.5 mg or 1 mg and $499 at 2 mg. So, at those regular prices, Zepbound 2.5 mg costs less than Ozempic 0.5 mg or 1 mg. From 5 mg up, Zepbound costs more than Ozempic 1 mg, and less than Ozempic 2 mg as long as you refill on time. New Ozempic patients pay a lower price for their first fills at the lowest doses, so compare with what you actually pay now.
Vials are a new routine if you’re used to a pen. The label says to use a syringe that can measure your dose, and a new syringe and needle for every injection. The savings card terms for insured patients are written for the single-dose pen. If your commercial plan covers it, the card can bring a pen fill down to $25. If your plan doesn’t cover it, the card price is $499 a month. See Zepbound cost.
How does coverage change?
A plan that has been paying for Ozempic has been paying for a diabetes medicine. A Zepbound prescription gets judged against the plan’s rules for weight management or sleep apnea, with its own prior authorization (the plan’s approval before it pays).
If you’re on Medicare, CMS lists type 2 diabetes and moderate to severe obstructive sleep apnea as uses that can be covered under Part D, while the law excludes drugs used for weight loss. The Medicare GLP-1 Bridge covers only the Zepbound KwikPen, and people with type 2 diabetes aren’t eligible for it. Read Medicare and Zepbound before you assume there’s a way to get it covered.
What to raise with your prescriber
- If you have type 2 diabetes, ask how your blood sugar will be managed after the change, since Zepbound isn’t approved for blood sugar control.
- The Zepbound label says to consider lowering insulin or sulfonylurea (a type of diabetes pill) doses when starting, to lower the risk of low blood sugar.
- If you use birth control pills, the label advises a non-oral method, or an added barrier method, for 4 weeks after starting and after each dose increase.
- Ask which form you’re being prescribed (vial, single-dose pen or KwikPen), because price and coverage differ by form.
- Ask for the date of your first Zepbound dose, counted from your last Ozempic dose.
The switching planner lets you check other pairs, and the Zepbound guide covers the medicine in depth.
Frequently asked questions
What is the equivalent dose of Zepbound to Ozempic?
No label gives one. Ozempic is semaglutide and Zepbound is tirzepatide, and neither label matches a dose of one to a dose of the other. The Zepbound label states a starting dose of 2.5 mg once weekly for 4 weeks, and says that dose is for getting started, not for staying on. Your prescriber decides what to prescribe.
Can I use Ozempic and Zepbound at the same time?
The Zepbound label says using it with any GLP-1 receptor agonist isn't recommended, and Ozempic is one. So a switch means Ozempic ends before Zepbound begins. The labels don't say how many days should pass between the two. Ask your prescriber for the exact date of your first Zepbound dose.
Is Zepbound cheaper than Ozempic if I pay cash?
It depends on both doses. At Ozempic's regular NovoCare prices, Zepbound 2.5 mg costs less than Ozempic 0.5 mg or 1 mg. Higher Zepbound doses cost more than Ozempic 1 mg, and less than Ozempic 2 mg as long as you refill on time. Zepbound vials through LillyDirect are $299 a month at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg and above when you refill within 45 days. Ozempic is $349 at 0.5 mg and 1 mg and $499 at 2 mg.
Will my insurance cover Zepbound if it covered Ozempic?
Don't assume it will. Ozempic is approved for type 2 diabetes. Zepbound is approved for weight reduction, and for obstructive sleep apnea in adults with obesity, so your plan applies different rules and will want a new prior authorization. On Medicare, the Part D law excludes drugs used for weight loss, and people with type 2 diabetes aren't eligible for the GLP-1 Bridge.
Sources (11)
- 1.FDA label (DailyMed): Zepbound prescribing information, section 1
“ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
- 2.FDA label (DailyMed): Zepbound prescribing information, section 2.1
“The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.”
- 3.FDA label (DailyMed): Zepbound prescribing information, section 7.1
“ZEPBOUND lowers blood glucose. When initiating ZEPBOUND, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) to reduce the risk of hypoglycemia [see Warnings and Precautions (5.7)].”
- 4.FDA label (DailyMed): Zepbound prescribing information, section 8.3
“Use of ZEPBOUND may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation [see Drug Interactions (7.2) and Clinical Pharmacology (12.2, 12.3)].”
- 5.FDA label (DailyMed): Zepbound prescribing information, section 2.4
“Instruct patients using ZEPBOUND vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection.”
- 6.Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
“The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
- 7.CMS: Information for Part D Plans
“Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
- 8.
- 9.
- 10.
- 11.
